Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | GPRIN1 | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-08 |
mRNA | FIZ1 | CTRPv2 | pan-cancer | AAC | 0.18 | 7e-08 |
mRNA | FBRSL1 | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-08 |
mRNA | PIDD1 | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-08 |
mRNA | RP11-212D19.4 | CTRPv2 | pan-cancer | AAC | -0.18 | 8e-08 |
mRNA | ZNF852 | CTRPv2 | pan-cancer | AAC | 0.2 | 8e-08 |
mRNA | PAFAH1B3 | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-08 |
mRNA | MAST1 | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-08 |
mRNA | C20orf96 | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-08 |
mRNA | SAMD1 | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-08 |